Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out

John Carroll

Editor & Founder

Eli Lilly cut 3 early and mid-stage cancer drug programs from the pipeline today, 3 weeks after the new oncology team under Josh Bilenker nixed an alliance it had underway in the field with NextCure.

I’m still lining up the drugs with the program, but the targets make for an interesting list.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Novartis unveils new brand identity after Sandoz spinoff

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Josh Bilenker’s team at Eli Lil­ly chops 3 can­cer drug pro­grams in pipeline cleanup as their $1.6B IL-10 ef­fort flames out

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

Supreme Court weighs in on Pur­due Phar­ma's bank­rupt­cy, with an eye to­ward opi­oid vic­tims

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Josh Bilenker’s team at Eli Lilly chops 3 cancer drug programs in pipeline cleanup as their $1.6B IL-10 effort flames out

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Novartis unveils new brand identity after Sandoz spinoff

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing